Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 13 studies | 22% ± 8% | |
lung | 10 studies | 24% ± 8% | |
brain | 6 studies | 31% ± 7% | |
bone marrow | 4 studies | 17% ± 1% | |
eye | 4 studies | 22% ± 8% | |
intestine | 4 studies | 24% ± 11% | |
pancreas | 3 studies | 36% ± 11% | |
kidney | 3 studies | 18% ± 2% | |
placenta | 3 studies | 20% ± 3% | |
skin | 3 studies | 43% ± 38% | |
breast | 3 studies | 20% ± 2% | |
lymph node | 3 studies | 20% ± 2% | |
liver | 3 studies | 29% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 3334.24 | 21 / 21 | 100% | 70.98 | 504 / 504 |
breast | 100% | 4315.81 | 459 / 459 | 100% | 97.28 | 1118 / 1118 |
esophagus | 100% | 3478.44 | 1445 / 1445 | 100% | 71.24 | 183 / 183 |
liver | 100% | 2363.65 | 226 / 226 | 100% | 36.40 | 406 / 406 |
lung | 100% | 3987.76 | 578 / 578 | 100% | 78.30 | 1155 / 1155 |
ovary | 100% | 3242.49 | 180 / 180 | 100% | 74.74 | 430 / 430 |
prostate | 100% | 3050.23 | 245 / 245 | 100% | 60.29 | 502 / 502 |
stomach | 100% | 2832.76 | 359 / 359 | 100% | 64.79 | 286 / 286 |
uterus | 100% | 3469.52 | 170 / 170 | 100% | 83.82 | 459 / 459 |
pancreas | 100% | 2114.92 | 327 / 328 | 100% | 56.24 | 178 / 178 |
thymus | 100% | 3316.33 | 653 / 653 | 100% | 65.43 | 603 / 605 |
intestine | 100% | 3438.67 | 966 / 966 | 100% | 65.46 | 525 / 527 |
skin | 100% | 5586.98 | 1809 / 1809 | 100% | 115.34 | 470 / 472 |
kidney | 100% | 2608.67 | 89 / 89 | 99% | 52.14 | 894 / 901 |
brain | 98% | 1979.10 | 2591 / 2642 | 100% | 60.53 | 705 / 705 |
adrenal gland | 100% | 4293.38 | 258 / 258 | 97% | 40.88 | 224 / 230 |
adipose | 100% | 3995.41 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 72.56 | 29 / 29 |
muscle | 100% | 3278.88 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3969.25 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 83.23 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 48.43 | 1 / 1 |
blood vessel | 100% | 2755.52 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 97% | 2017.66 | 837 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 60.07 | 77 / 80 |
peripheral blood | 91% | 2517.83 | 850 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0070925 | Biological process | organelle assembly |
GO_1903679 | Biological process | positive regulation of cap-independent translational initiation |
GO_0045948 | Biological process | positive regulation of translational initiation |
GO_0034063 | Biological process | stress granule assembly |
GO_0043488 | Biological process | regulation of mRNA stability |
GO_0006402 | Biological process | mRNA catabolic process |
GO_0045087 | Biological process | innate immune response |
GO_0007276 | Biological process | gamete generation |
GO_0061157 | Biological process | mRNA destabilization |
GO_2000232 | Biological process | regulation of rRNA processing |
GO_0071425 | Biological process | hematopoietic stem cell proliferation |
GO_0006959 | Biological process | humoral immune response |
GO_0001556 | Biological process | oocyte maturation |
GO_0048598 | Biological process | embryonic morphogenesis |
GO_1902036 | Biological process | regulation of hematopoietic stem cell differentiation |
GO_0007284 | Biological process | spermatogonial cell division |
GO_2000737 | Biological process | negative regulation of stem cell differentiation |
GO_0098508 | Biological process | endothelial to hematopoietic transition |
GO_0050767 | Biological process | regulation of neurogenesis |
GO_0060339 | Biological process | negative regulation of type I interferon-mediated signaling pathway |
GO_0045746 | Biological process | negative regulation of Notch signaling pathway |
GO_0030155 | Biological process | regulation of cell adhesion |
GO_1903538 | Biological process | regulation of meiotic cell cycle process involved in oocyte maturation |
GO_0034451 | Cellular component | centriolar satellite |
GO_0036464 | Cellular component | cytoplasmic ribonucleoprotein granule |
GO_0000932 | Cellular component | P-body |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0010494 | Cellular component | cytoplasmic stress granule |
GO_0005634 | Cellular component | nucleus |
GO_0062153 | Molecular function | C5-methylcytidine-containing RNA reader activity |
GO_0003729 | Molecular function | mRNA binding |
GO_1990247 | Molecular function | N6-methyladenosine-containing RNA reader activity |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | YTHDF2 |
Protein name | YTH N6-methyladenosine RNA binding protein 2 YTH domain-containing family protein 2 (DF2) (CLL-associated antigen KW-14) (High-glucose-regulated protein 8) (Renal carcinoma antigen NY-REN-2) YTH domain-containing family protein |
Synonyms | HGRG8 |
Description | FUNCTION: Specifically recognizes and binds N6-methyladenosine (m6A)-containing RNAs, and regulates their stability . M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in mRNA stability and processing . Acts as a regulator of mRNA stability by promoting degradation of m6A-containing mRNAs via interaction with the CCR4-NOT and ribonuclease P/MRP complexes, depending on the context . The YTHDF paralogs (YTHDF1, YTHDF2 and YTHDF3) share m6A-containing mRNAs targets and act redundantly to mediate mRNA degradation and cellular differentiation . M6A-containing mRNAs containing a binding site for RIDA/HRSP12 (5'-GGUUC-3') are preferentially degraded by endoribonucleolytic cleavage: cooperative binding of RIDA/HRSP12 and YTHDF2 to transcripts leads to recruitment of the ribonuclease P/MRP complex . Other m6A-containing mRNAs undergo deadenylation via direct interaction between YTHDF2 and CNOT1, leading to recruitment of the CCR4-NOT and subsequent deadenylation of m6A-containing mRNAs . Required maternally to regulate oocyte maturation: probably acts by binding to m6A-containing mRNAs, thereby regulating maternal transcript dosage during oocyte maturation, which is essential for the competence of oocytes to sustain early zygotic development (By similarity). Also required during spermatogenesis: regulates spermagonial adhesion by promoting degradation of m6A-containing transcripts coding for matrix metallopeptidases (By similarity). Also involved in hematopoietic stem cells specification by binding to m6A-containing mRNAs, leading to promote their degradation . Also acts as a regulator of neural development by promoting m6A-dependent degradation of neural development-related mRNA targets (By similarity). Inhibits neural specification of induced pluripotent stem cells by binding to methylated neural-specific mRNAs and promoting their degradation, thereby restraining neural differentiation . Regulates circadian regulation of hepatic lipid metabolism: acts by promoting m6A-dependent degradation of PPARA transcripts . Regulates the innate immune response to infection by inhibiting the type I interferon response: acts by binding to m6A-containing IFNB transcripts and promoting their degradation . May also act as a promoter of cap-independent mRNA translation following heat shock stress: upon stress, relocalizes to the nucleus and specifically binds mRNAs with some m6A methylation mark at their 5'-UTR, protecting demethylation of mRNAs by FTO, thereby promoting cap-independent mRNA translation . Regulates mitotic entry by promoting the phase-specific m6A-dependent degradation of WEE1 transcripts . Promotes formation of phase-separated membraneless compartments, such as P-bodies or stress granules, by undergoing liquid-liquid phase separation upon binding to mRNAs containing multiple m6A-modified residues: polymethylated mRNAs act as a multivalent scaffold for the binding of YTHDF proteins, juxtaposing their disordered regions and thereby leading to phase separation . The resulting mRNA-YTHDF complexes then partition into different endogenous phase-separated membraneless compartments, such as P-bodies, stress granules or neuronal RNA granules . May also recognize and bind RNAs modified by C5-methylcytosine (m5C) and act as a regulator of rRNA processing . .; FUNCTION: (Microbial infection) Promotes viral gene expression and replication of polyomavirus SV40: acts by binding to N6-methyladenosine (m6A)-containing viral RNAs . .; FUNCTION: (Microbial infection) Promotes viral gene expression and virion production of kaposis sarcoma-associated herpesvirus (KSHV) at some stage of the KSHV life cycle (in iSLK.219 and iSLK.BAC16 cells) . Acts by binding to N6-methyladenosine (m6A)-containing viral RNAs . . FUNCTION: Specifically recognizes and binds N6-methyladenosine (m6A)-containing RNAs, and regulates mRNA stability. M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in mRNA stability and processing. . |
Accessions | S4R3V3 ENST00000496288.5 B5BU99 ENST00000373812.8 [Q9Y5A9-1] ENST00000542507.5 [Q9Y5A9-1] ENST00000541996.5 [Q9Y5A9-2] S4R3J8 ENST00000474884.5 Q9Y5A9 |